Cluster Headache Syndrome (Cluster Headache) Pipeline Review, H1 2019 Report Featuring Clexio Biosciences, Crossject, Eli Lilly and Co, Novartis, Teva Pharmaceutical & TrioxBio - ResearchAndMarkets.com
DUBLIN--(BUSINESS WIRE)--May 23, 2019--
The “Cluster Headache Syndrome (Cluster Headache) - Pipeline Review, H1 2019” drug pipelines has been added to ResearchAndMarkets.com’s offering.
Cluster Headache Syndrome - Pipeline Review, H1 2019, provides comprehensive information on the therapeutics under development for Cluster Headache Syndrome (Central Nervous System), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.
The Cluster Headache Syndrome (Central Nervous System) pipeline guide also reviews of key players involved in therapeutic development for Cluster Headache Syndrome (Cluster Headache) and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Phase III, Phase II, Phase I and Preclinical stages are 2, 2, 1 and 2 respectively. Similarly, the Universities portfolio in Phase I stages comprises 1 molecules, respectively.
Cluster Headache Syndrome (Central Nervous System) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage.
- The pipeline guide provides a snapshot of the global therapeutic landscape of Cluster Headache Syndrome (Central Nervous System).
- The pipeline guide reviews pipeline therapeutics for Cluster Headache Syndrome (Central Nervous System) by companies and universities/research institutes based on information derived from company and industry-specific sources.
- The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.
- The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.
- The pipeline guide reviews key companies involved in Cluster Headache Syndrome (Central Nervous System) therapeutics and enlists all their major and minor projects.
- The pipeline guide evaluates Cluster Headache Syndrome (Central Nervous System) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.
- The pipeline guide encapsulates all the dormant and discontinued pipeline projects.
- The pipeline guide reviews latest news related to pipeline therapeutics for Cluster Headache Syndrome (Central Nervous System)
- Clexio Biosciences Ltd
- Crossject SA
- Eli Lilly and Co
- Novartis AG
- Teva Pharmaceutical Industries Ltd
- TrioxBio Inc
For more information about this drug pipelines report visit https://www.researchandmarkets.com/r/5ajxua
View source version on businesswire.com:https://www.businesswire.com/news/home/20190523005447/en/
Laura Wood, Senior Press Manager
For E.S.T Office Hours Call 1-917-300-0470
For U.S./CAN Toll Free Call 1-800-526-8630
For GMT Office Hours Call +353-1-416-8900
INDUSTRY KEYWORD: HEALTH PHARMACEUTICAL
SOURCE: Research and Markets
Copyright Business Wire 2019.
PUB: 05/23/2019 09:40 AM/DISC: 05/23/2019 09:40 AM